SCHEMBL1610352

SCHEMBL1610352

C=[C]c1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 3/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
KDM4E B2RXH2 2/20 0.53
LMNA P02545 2/20 0.53
SRD5A2 P31213 1/20 0.47
CYP1A2 P05177 5/20 0.45
CYP3A4 P08684 4/20 0.45
HSD17B10 Q99714 2/20 0.43
MAOA P21397 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
ADRA2A P08913 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
TSHR P16473 2/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612049 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL2355804 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL739759 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL29731284 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL4620527 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL31441011 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL8911138 0.79 GRM5 (0.56) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
Fluorene SCHEMBL28257966 0.79 MAOA (0.56) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL2720506 0.78 ALDH1A1 (0.70) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
Fluorene SCHEMBL28822333 0.76 MAOA (0.59) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257265-B1 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS BIOAGENCY AG (DE) 2004-01-21 EP claimed
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections JOMAA PHARMAKA GMBH (DE) 2003-02-20 US claimed
EP-1257265-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS Jomaa Pharmaka GmbH (DE) 2002-11-20 EP claimed
WO-2001070026-A2 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES JOMAA PHARMAKA GMBH (DE) 2001-09-27 WO claimed
WO-2001062709-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-08-30 WO claimed
EP-1068176-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS Jomaa, Hassan (DE) 2001-01-17 EP claimed
WO-2000027803-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS JOMAA, HASSAN (DE) 2000-05-18 WO claimed
US-20110087034-A1 Organic Semiconductor Material SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2011-04-14 US disclosed
EP-2248818-A1 ORGANIC SEMICONDUCTOR MATERIAL Sumitomo Chemical Company, Limited (JP) 2010-11-10 EP disclosed
EP-1257265-B1 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS BIOAGENCY AG (DE) 2004-01-21 EP disclosed
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections JOMAA PHARMAKA GMBH (DE) 2003-02-20 US disclosed
EP-1257265-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS Jomaa Pharmaka GmbH (DE) 2002-11-20 EP disclosed
WO-2001070026-A2 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES JOMAA PHARMAKA GMBH (DE) 2001-09-27 WO disclosed
WO-2001062709-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-08-30 WO disclosed
EP-1068176-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS Jomaa, Hassan (DE) 2001-01-17 EP disclosed
WO-2000027803-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS JOMAA, HASSAN (DE) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections HRH2, ASPH, NQO2 SMN1; SMN2 4081/4885ALDH1A1 1419/4885NPC1 1407/4885
US-20110087034-A1 Organic Semiconductor Material OR10J3, TST, OR51E2 SMN1; SMN2 3123/4885ALDH1A1 137/4885NPC1 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.